Criteria for surgical tactics in patients with proliferative diabetic retinopathy (PDR) and cataract

Session Details

Session Title: Free Paper Session 26: Vitreoretinal Surgery VI

Session Date/Time: Sunday 10/09/2017 | 10:00-11:30

Paper Time: 10:12

Venue: Room 116

First Author: : A.Kazennov RUSSIA

Co Author(s): :    A. Chuprov   A. Gorbunov   I. Kazennova                       

Abstract Details

Purpose:

To estimate the effectiveness of using criteria for management of surgical treatment.

Setting:

Orenburg branch of S.Fyodorov Eye Microsurgery Federal State Institution

Methods:

70 patients (100 eyes) with proliferative diabetic retinopathy were operated using the developed criteria for management of surgical treatment. All patients were divided into 6 groups. Lens density was assessed with LOCS III, the degree of diabetes with ETDRS. 1st group: PDR 3, nuclear density 2+, 3-4+ and opacity of cortical layers under the posterior capsule of the lens; 2nd group: PDR 4, nuclear density 1-2+, 3-4+; 3rd group: PDR 5, nuclear density 2+, 3-4+; 4th group: PDR 3-5 and nuclear density above 4+ degree; 5th group: PDR 3-5, the density of the nucleus of any degree, severe course of diabetes; 6th group: PDR 3, nuclear density 1-2+ degree.

Results:

44 patients (63 eyes) from groups 1, 2, 3 and 5 underwent combined surgery of phacoemulsification with implantation of flexible intraocular lens and 25G vitrectomy. 17 patients (23 eyes) from group 4 underwent phacoemulsification with IOL implantation as I stage and 25 G vitrectomy as II stage. 9 patients (14 eyes) from group 6 underwent 25 G vitrectomy as I stage and phacoemulsification with IOL implantation as II stage. In patients from groups 4 and 6 postoperative period proceeded without complications, in groups 1, 2, 3, and 5 in the early postoperative period exudative events were observed, that were stopped by 3-5 days against the background of increased anti-inflammatory therapy.

Conclusions:

Application of the developed criteria allows choosing the most safe and effective management of surgical treatment in patients with proliferative diabetic retinopathy and cataract.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy